Supplemental Figure S9 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma
Key Points
Key points are not available for this paper at this time.
Abstract
Evaluation of the DNA-PK inhibitors plus TOP2 poisons in preclinical models of EWS
Supplemental Figure S9 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma | Synapse